NewsIn memory
Gabriel García Márquez and Lymphoma: What the Diagnosis Means
The Nobel laureate Gabriel García Márquez was treated for lymphoma in 1999. Here's what lymphoma really is, in calm, accurate terms.
A plain-language summary based on public reporting and trusted sources, linked below.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What the record actually says
Gabriel García Márquez wrote One Hundred Years of Solitude and won the Nobel Prize in Literature. He died on April 17, 2014, at the age of 87.
His obituary in The Guardian states it plainly: "In 1999 the writer was diagnosed with lymphoma, or cancer of the immune system. The illness was to cloud his final years, requiring constant treatment."
That is the extent of the public record. No subtype, no stage, and no treatment details were released. This page will not supply them. What it will do is explain what "lymphoma" means, because the word covers dozens of separate diseases.
One word, many diseases
Lymphoma is cancer of lymphocytes. Those are white blood cells that patrol the body through the lymph system, a network of vessels, nodes, and organs. When a lymphocyte turns cancerous, its copies pile up in nodes, in the spleen, in bone marrow, and sometimes elsewhere.
The first split is Hodgkin lymphoma versus non-Hodgkin lymphoma. Non-Hodgkin lymphoma is far larger and far more varied. The American Cancer Society projects about 79,320 new cases and 19,970 deaths from it in the US in 2026, the figures SEER carries. About 85% arise from B cells.
The fork that decides everything
NCI sorts non-Hodgkin lymphomas into two prognostic groups, and the logic is counterintuitive.
Indolent lymphomas grow slowly. NCI describes a relatively good prognosis, with median survival as long as 20 years. But it adds a hard qualifier: indolent disease "is usually not curable in advanced clinical stages."
Aggressive lymphomas grow fast. Untreated, they are dangerous within months. Yet NCI states that more than 70% of patients with aggressive non-Hodgkin lymphoma can be cured.
So the slow one is often controlled for decades without ever being cured. The fast one is often cured outright. Which group a person falls into shapes every decision that follows.
The names you are likely to hear
Follicular lymphoma is the most common indolent type. NCI puts it at 20% of all non-Hodgkin lymphoma, and as many as 70% of indolent cases. Median survival runs 8 to 15 years, even in advanced stages.
Diffuse large B-cell lymphoma is the main aggressive type. It is also the one most often cured.
Marginal zone lymphomas are a third family. They include gastric MALT lymphoma, which starts in the stomach lining, along with extragastric and splenic forms.
How it announces itself
Most patients are already at stage III or IV when diagnosed. That sounds alarming, but stage means something different here than in solid tumors, because lymph tissue is everywhere by design.
Indolent lymphomas often involve bone marrow. NCI notes liver involvement is especially common in low-grade disease. Nodes on both sides of the body may enlarge without any pattern.
When to get a lump looked at
Most swollen glands are infection. A node that swells with a sore throat and shrinks over two or three weeks is usually nothing. Book an appointment if you have:
- A lump in the neck, armpit, or groin that is painless, rubbery, and still there after four weeks
- Any node that is clearly getting bigger week over week
- Drenching night sweats that soak through your bedclothes
- Fever above 100.4°F with no infection to explain it
- Losing more than 10% of your body weight in six months without trying
- Itching all over the body with no rash
Seek same-day care for new shortness of breath, facial or neck swelling, or a voice change. A mass in the chest can press on the airway or on the large vein returning blood from the head.
The three middle items on that list are called B symptoms. They are formally recorded because they affect staging and treatment.
The biopsy that settles it
Blood tests cannot diagnose lymphoma. Tissue can. NCI recommends lymph node biopsies whenever possible.
The kind of biopsy matters. A large French study found that core needle biopsy gave a definite diagnosis in 92.3% of cases, while excisional biopsy, removing the whole node, gave one in 98.1%. Pathologists then run immunophenotyping, which identifies the proteins on the cell surface. Those markers are what name the subtype.
Staging, and scoring the risk
Staging uses the Lugano classification. Stage I means one lymphatic site. Stage II means two or more node regions on the same side of the diaphragm. Stage III means node regions on both sides. Stage IV means widespread involvement of one or more organs outside the lymph system.
For follicular lymphoma, doctors add a score called the FLIPI. It counts five factors: age, LDH level, stage, hemoglobin, and the number of nodal areas involved. NCI reports 10-year survival of 67% for people with zero or one factor, and 36% for those with four or five.
Sometimes the right treatment is none yet
This surprises people. For advanced-stage follicular lymphoma, NCI lists watchful waiting as an option, meaning treatment is deferred until symptoms appear. Since the disease is not curable at that stage, and treatment carries real costs, starting early does not always help.
When treatment does begin, rituximab is the backbone. It is an antibody that targets the CD20 protein on B cells, and it is used alone or with chemotherapy. CHOP chemotherapy combines cyclophosphamide, doxorubicin, vincristine, and prednisone. Added to rituximab, it becomes R-CHOP, the standard for many aggressive lymphomas. Bendamustine combinations and BTK inhibitors such as ibrutinib and zanubrutinib serve other subtypes.
The group picture
SEER, the federal cancer surveillance program, puts five-year relative survival for all non-Hodgkin lymphoma at 74.3%. By stage it runs 87.6% for stage I, 79.7% for stage II, 74.0% for stage III, and 63.6% for stage IV.
Notice how shallow that decline is compared with most cancers. It reflects how treatable many of these diseases have become. It also pools dozens of subtypes with very different behavior, so it describes a population and not a person.
Sources
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Lymphoma. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.